Evidence map›Paper›PMID 21951539›Full record

ArticleMethods in cell biology2011

Zebrafish models of rhabdomyosarcoma.

Eleanor Y Chen, David M Langenau

Open access · greenAbstract read
In one paragraph

Article in Methods in cell biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
13.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Eleanor Y ChenMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
David M Langenau
Massachusetts General Hospital · US

Funding

VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
Genetics of RhabdomyosarcomaR01CA154923 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2011 to 2021
$3.8M
Identification of self-renewal programs in muscle stem cellsK01AR055619 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2008 to 2012
$743k
Chemical Inhibitors of Rhabdomyosarcoma Self-RenawalR21CA156056 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2011 to 2012
$417k
NCI NIH HHS R01 CA154923NCI NIH HHS R21 CA156056NHLBI NIH HHS T32 HL007627NIAMS NIH HHS K01 AR055619NIAMS NIH HHS K01AR05562190-01 A1NIAMS NIH HHS K01AR05562190-S1
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS), an aggressive malignant neoplasm that shows features of skeletal muscle, is the most common soft tissue tumor of childhood. In children, the major subtypes are embryonal and alveolar. Although localized disease responds to a multimodal treatment, the prognosis for patients with high-risk features and metastasis remains dismal. Several in vivo models of RMS have been developed in mouse, human xenografts, zebrafish, and Drosophila to better understand the underlying mechanisms governing malignancy. The findings so far have indicated the potential role of skeletal muscle precursor cells in malignant transformation. To better understand histogenesis and different aspects of tumorigenesis in RMS, we have previously developed a robust zebrafish model of kRAS-induced RMS, which shares morphologic and immunophenotypic features with the human counterpart. Cross-species mircroarray comparisons confirm that conserved genetic pathways drive RMS growth. The ease for ex vivo manipulation allows the development of different transgenic and co-injection strategies to induce tumor formation in zebrafish. In contrast to other vertebrate model systems, the tumor onset in zebrafish is short, allowing for efficient study of different tumor processes including tumor growth, self-renewal, and maintenance.

Indexed as

AnimalsAnimals, Genetically ModifiedCell Transformation, NeoplasticChildComputational BiologyEmbryo, NonmammalianGreen Fluorescent ProteinsHumansMedical OncologyMiceMicroinjectionsMolecular ImagingNeoplasm TransplantationPlasmidsPromoter Regions, GeneticProto-Oncogene ProteinsGreen Fluorescent ProteinsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID21951539
PMCPMC3615705
OpenAlexW1601691786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.